Stock screener

RLAY

Conviction 100HealthcareScan · Thu, Jun 25, 2026
RLAY$17.84-1.03%
ResistanceSupportVol 14Insider sell
63 bars
5
Vol MA14 4.22M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Relay Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.relaytx.com ↗
Price17.84
Change-1.03%
Gap+1.39%
Rel volume2.02×
Avg volume4.49M
Avg $ vol69.74M
SMA 2015.18
SMA 5014.39
SMA 2009.58
Price vs 50+23.97%
Price vs 200+86.11%
MA stackbullish
50/200 cross—
Supertrendup · 14.99
RSI (14)72
MACD hist0.35
MACD crossbull · 8d
Stoch %K / %D82 / 88
ADX (14)27
+DI / −DI38 / 13
RSI divergence—
MACD divergence—
ATR %+6.08%
ADR %6.60%
52w high18.02
52w low3.22
From 52w high-1.03%
Above 52w low+453.88%
New 52w highNo
SqueezeOff
Bollinger width37.23%
%B0.97
Donchian pos82.04%
Donchian high18.91
Donchian low12.93
AVWAP (52w high)18.13
vs AVWAP high-1.63%
AVWAP (52w low)10.37
vs AVWAP low+71.98%
OBV trendUp
Chaikin MF (20)-0.32
Today vs 20d2.02×
Avg vol (14d)4.22M
Avg vol (20d)4.49M
Avg $ vol (20d)69.74M
Market cap3.42B
RS 3m (vs SPY)+78.63%
RS 6m (vs SPY)+106.79%
RS line new highYes
Trend template8/8
Technical rank95.2
1 week+14.62%
1 month+25.86%
3 months+85.78%
6 months+107.14%
1 year+438.82%
YTD+118.03%
P/E-12.36
P/B5.32
P/S222.53
P/FCF-14.49
EPS-1.61
Div yield—
ROE-43.05%
ROA-39.52%
Debt/Eq—
Current22.13
EV/EBITDA—
Gross margin—
Net margin—
Rev growth53.44%
EPS growth18.13%
Price target23.56
Target upside32.10%
Analyst ratingBuy
Institutional89.47%
Ent. value3.21B
Revenue3M
Net income-73.29M
Gross profit—
Free cash flow-235.87M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out191.59M
Employees192
ListedThu, Jul 16, 2020
Free float116.71M
Float %65.3%
Short interest34.39M
Days to cover5.7d
Short volume55.0%
Squeeze score90 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.41 · 3 est
Last EPS vs est−$0.41 vs −$0.35
Last surprise-17.1% miss
Setup gradeA+
Conviction100 / 100
Pattern quality—
Tech rank95.2 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance16.46
Support11.69
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RLAY

All disclosures →
No recent disclosed trades by Congress in RLAY. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RLAY · 4 buys · 6 sells

InsiderSideShares
Bergstrom Donald A
President, R&D · Common Stock · 2026-06-22
Exercise93.46K
Bergstrom Donald A
President, R&D · Common Stock · 2026-06-22
Sell93.46K
Bergstrom Donald A
President, R&D · Stock Option (Right to Buy) · 2026-06-22
Exercise93.46K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell17.72K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise56.32K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell56.32K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise61.56K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell61.56K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Exercise51.56K
Catinazzo Thomas
Chief Financial Officer · Common Stock · 2026-06-22
Sell51.56K

SEC filings

EDGAR filings in RLAY · 3 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.